Jump to content
  • History of the RRDi


    There was a post at a Yahoo group in  November 23, 2002 that started the idea of making a non profit organization for rosacea sufferers to collaborate together. 

    The Rosacea Research & Development Institute began as an idea by the founder, Brady Barrows, on November 23, 2002 when he founded the following yahoo group:

    health.groups.yahoo.com/group/international-rosacea-society

    The above yahoo group was changed on July 24, 2004 to:

    health.groups.yahoo.com/group/irosacea

    And then later changed on February 14, 2005 to this yahoo group:

    health.groups.yahoo.com/group/rosacea-research

    The above yahoo group was deleted June 7, 2006 since the private forum for corporate members began in April/May 2006. Since then, Yahoo Groups has been removed from the internet. 

    A need for a non-profit organization that heard the voice of rosaceans suffering from this disease was seen early on and discussion continues to this day. Upon moving to Hawaii the founder discovered that forming a non-profit organization in this state would be simpler than in other states and applied for approval as a non-profit corporation. A Charter was set up. The non profit recognition was approved on June 7, 2004 by the State of Hawaii and after a lengthy period, tax-exempt approval as a 501 (c) (3) non profit organization was obtained by the IRS in January 2006 and recognition was effective back to June 7, 2004. This process took over a year and a half. More details of all this are written in the article Why Form Another Non Profit Organization For Rosacea?

    The Board of Directors were chosen by the corporation members and the officers were appointed in January 2005. More board members were added in 2006 and later.

    The web site is constantly being improved by volunteers. Volunteers are seeking funding and you can join us to seek corporate donations, seek grants, or find the best minds to join the RRDi MAC, the only medical advisory committee volunteering to find a cure for rosacea, listen to corporate RRDi members' concerns and advise the board of directors on the direction the RRDi should go. Several private member forums were experimented which have not proven popular. For a number of years the RRDi recommended Warren Stuart's www.rosaceagroup.org as the public forum and volunteers have made the private forum for corporate members on the irosacea.org web site. To use the public forum you must join the RRDi. This public corporate member forum is where decisions are discussed. The public forum can be found at this url:

    http://irosacea.org/forums

    Steve Andreessen spent many volunteer hours on not only the above IPB forum (now called Invision Community)  but also our web site. Warren Stuart has also spent many hours volunteering on the web site as well. Under Warren's direction we purchased the Invision Power Services forum (now called Invision Community). Sadly, Warren Stuart passed away. David Pascoe took over Warren's Rosacea Forum. The focus of the RRDi for years has been to gather together the best minds on rosacea into the RRDi Medical Advisory Committee, gathering volunteers to raise public awareness of the RRDi in the Public Relations Committee and to increase RRDi membership, and finally to increase funding through volunteer efforts in the Funding Committee by volunteers. You can see the results of all this volunteer effort and you can become part of it by joining with just an email address. You may want to read the Message from the Founder and our post about Anonymity, Transparency and Posting before joining.

    The RRDi has been affiliated with sponsoring Tapatalk since some users prefer using Tapatalk on mobile devices. In 2019 we have sponsored a private Tapatalk Rosaceans Forum



  • Posts

    • Cornea. 2024 Jul 5. doi: 10.1097/ICO.0000000000003627. Online ahead of print. ABSTRACT PURPOSE: The purpose of this study was to report the outcomes of quantum molecular resonance (QMR) electrotherapy in the management of refractory pediatric ocular rosacea. METHODS: This is a retrospective case series on 3 female pediatric patients (ages 12, 15, 14 years) with ocular rosacea. Two patients presented with corneal stromal neovascularization and punctate epithelial erosions while 1 patient presented with corneal scarring and paracentral stromal thinning. After failing conservative management, the patients were treated with 4 consecutive QMR electrotherapy sessions with the intensity set at 5 corresponding on average to a power of 12 W, with 60 V voltage and 200 mA current. Informed consent was obtained for off-label use. Patients were assessed for changes in vision, foreign body sensation, tearing, photophobia, and redness at each visit to determine symptomatic improvement. Outcome measures include best-corrected visual acuity, use of supplemental therapies (eg topical steroids) for symptom relief, extent of corneal neovascularization via serial slitlamp photography, and corneal scar remodeling via high resolution anterior segment optical coherence tomography (OCT). RESULTS: Two of the 3 patients experienced improvement in visual acuity after QMR electrotherapy. Corneal neovascularization and scarring regressed significantly in all 3 patients. Two months post-QMR electrotherapy, corneal remodeling was evident on optical coherence tomography in 2 patients. All 3 patients were able to discontinue topical immunosuppressants and remain symptom-free at 1.5 years of follow-up. CONCLUSIONS: QMR electrotherapy is a promising alternative in the treatment of refractory ocular rosacea in childhood and puberty, and it may potentiate corneal remodeling. PMID:38967538 | DOI:10.1097/ICO.0000000000003627 {url} = URL to article
    • J Alzheimers Dis. 2024 Jun 28. doi: 10.3233/JAD-240198. Online ahead of print. ABSTRACT This manuscript reviews the significant skin manifestations of Lewy body disease, including Parkinson's disease and dementia with Lewy bodies, and the diagnostic utility of skin biopsy. Besides classic motor and cognitive symptoms, non-motor manifestations, particularly dermatologic disorders, can play a crucial role in disease presentation and diagnosis. This review explores the intricate relationship between the skin and Lewy body disease. Seborrheic dermatitis, autoimmune blistering diseases (bullous pemphigoid and pemphigus), rosacea, and melanoma are scrutinized for their unique associations with Parkinson's disease, revealing potential links through shared pathophysiological mechanisms. Advances in diagnostic techniques allow the identification of promising biomarkers such as α-synuclein in samples obtained by skin punch biopsy. Understanding the dermatologic aspects of Lewy body disease not only contributes to its holistic characterization but also holds implications for innovative diagnostic approaches. PMID:38968048 | DOI:10.3233/JAD-240198 {url} = URL to article
    • JAAD Int. 2024 May 6;16:112-118. doi: 10.1016/j.jdin.2024.04.009. eCollection 2024 Sep. ABSTRACT PMID:38957837 | PMC:PMC11217679 | DOI:10.1016/j.jdin.2024.04.009 {url} = URL to article
    • Clin Cosmet Investig Dermatol. 2024 Jun 26;17:1551-1552. doi: 10.2147/CCID.S484236. eCollection 2024. ABSTRACT [This corrects the article DOI: 10.2147/CCID.S473598.]. PMID:38952412 | PMC:PMC11215658 | DOI:10.2147/CCID.S484236 {url} = URL to article
    • Heliyon. 2024 Jun 1;10(11):e32275. doi: 10.1016/j.heliyon.2024.e32275. eCollection 2024 Jun 15. ABSTRACT A combination of benzoyl peroxide (BPO) and tretinoin is recommended for treating acne; however, concurrent administration can be irritating, and coformulation is prevented by BPO-mediated oxidation of tretinoin. In rosacea, benzoyl peroxide has been shown to be efficacious; however, its use has been limited by poor tolerability. To overcome these limitations, the active ingredients can be encapsulated within silica microcapsules. The US Food and Drug Administration has approved 2 products using this technology, a combination of encapsulated benzoyl peroxide and encapsulated tretinoin product for acne vulgaris and encapsulated benzoyl peroxide to treat inflammatory lesions in rosacea. The active ingredients are released through small channels in the silica shell, gradually releasing the active ingredients to the skin. This study describes the stability and release profiles of encapsulated tretinoin and encapsulated benzoyl peroxide from the silica shell in physiologically relevant conditions and provides differentiation from traditional formulations. PMID:38947450 | PMC:PMC11214359 | DOI:10.1016/j.heliyon.2024.e32275 {url} = URL to article
×
×
  • Create New...

Important Information

Terms of Use